Premium
Osteoarthritis and Rheumatoid Arthritis: Will New Data Clarify the Risk:Benefit Ratio of Cyclooxygenase‐2 Inhibitors?
Author(s) -
Gogol Manfred
Publication year - 2003
Publication title -
journal of the american geriatrics society
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.992
H-Index - 232
eISSN - 1532-5415
pISSN - 0002-8614
DOI - 10.1046/j.1532-5415.2003.515245.x
Subject(s) - medicine , rofecoxib , diclofenac , celecoxib , rheumatoid arthritis , aspirin , osteoarthritis , cyclooxygenase , intensive care medicine , pharmacology , alternative medicine , biochemistry , chemistry , pathology , enzyme